TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07645820: Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Sponsor: Castle Biosciences Incorporated · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 450 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$4,953,600

Rescue Site Savings

+$3,276,600

Unlock Full NCT07645820 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07645820 Rescue Dossier →